نتائج البحث

A mesoporous superparamagnetic iron oxide nanoparticle as a generic drug delivery system for tumor ferroptosis therapy.

• Authors : Yang J; School of Biomedical Engineering, Southern Medical University, 1023 Shatai South Road, Guangzhou, 510515, Guangdong, China.; Xiong W

Subjects: Ferroptosis*/Ferroptosis*/Ferroptosis*/drug effects ; Magnetic Iron Oxide Nanoparticles*/Magnetic Iron Oxide Nanoparticles*/Magnetic Iron Oxide Nanoparticles*/chemistry ; Drug Delivery Systems*/Drug Delivery Systems*/Drug Delivery Systems*/methods

• Source: Journal of nanobiotechnology [J Nanobiotechnology] 2024 Apr 24; Vol. 22 (1), pp. 204. Date of Electronic Publication: 2024 Apr 24.Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-3155

تفاصيل العنوان

Sorafenib regulates c-CBL gene-mediated chemoresistance in acute myeloid leukemia cells.

• Authors : Sun Q; Department of Geriatric Hematology and Oncology, Guangzhou First People's Hospital, Guangzhou, China.; Wu B

Subjects: Drug Resistance, Neoplasm*/Drug Resistance, Neoplasm*/Drug Resistance, Neoplasm*/genetics ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/drug therapy ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/genetics

• Source: Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2204620.Publisher: Taylor & Francis Country of Publication: England NLM ID: 9708388 Publication Model: Print Cited Medium: Internet ISSN: 1607-8454

تفاصيل العنوان

The Role of Bcl-2 and Beclin-1 Complex in "Switching" between Apoptosis and Autophagy in Human Glioma Cells upon LY294002 and Sorafenib Treatment.

• Authors : Zając A; Department of Functional Anatomy and Cytobiology, Institute of Biological Sciences, Maria Curie-Skłodowska University, Akademicka 19, 20-033 Lublin, Poland.; Maciejczyk A

Subjects: Glioma*/Glioma*/Glioma*/drug therapy ; Glioma*/Glioma*/Glioma*/pathology ; Phosphatidylinositol 3-Kinases*/Phosphatidylinositol 3-Kinases*/Phosphatidylinositol 3-Kinases*/metabolism

• Source: Cells [Cells] 2023 Nov 21; Vol. 12 (23). Date of Electronic Publication: 2023 Nov 21.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409

تفاصيل العنوان

Real-world evidence of sorafenib for the treatment of hepatocellular carcinoma: A single-center study.

• Authors : Lopez-Lopez A; Department of Pharmacy, University Hospital Complex of Vigo, Spain.; Gayoso-Rey M

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/pathology ; Liver Neoplasms*/Liver Neoplasms*/Liver Neoplasms*/drug therapy

• Source: Journal of cancer research and therapeutics [J Cancer Res Ther] 2023 Jul-Sep; Vol. 19 (5), pp. 1345-1349.Publisher: Medknow Publications Country of Publication: India NLM ID: 101249598 Publication Model: Print Cited Medium: Internet ISSN: 1998-4138

تفاصيل العنوان

Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC.

• Authors : Chan YT; School of Chinese Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong.; Wu J

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/genetics ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/metabolism

• Source: Molecular cancer [Mol Cancer] 2024 Apr 06; Vol. 23 (1), pp. 74. Date of Electronic Publication: 2024 Apr 06.Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598

تفاصيل العنوان

Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas.

• Authors : Cruz SM; Division of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA.; Iranpur KR

Subjects: Tyrosine Kinase Inhibitors* ; Sarcoma*/Sarcoma*/Sarcoma*/pathology; Humans

• Source: International journal of molecular sciences [Int J Mol Sci] 2024 Mar 15; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 15.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis.

• Authors : She, Xianhua¹ (AUTHOR); Yin, Donghong¹ (AUTHOR); Guo, Qian¹ (AUTHOR)

• Source: Scientific Reports. 3/8/2024, Vol. 14 Issue 1, p1-12. 12p.

تفاصيل العنوان

Potentiating sorafenib efficacy against hepatocellular carcinoma via a carrier-free nanomedicine of artesunate prodrug.

• Authors : Kun Liu¹; Kun Chen²; Xueyang Zhang¹

• Source: Smart Materials in Medicine. Mar2024, Vol. 5 Issue 1, p114-126. 13p.

تفاصيل العنوان

The potential anticancer effect of bee venom in combination with sorafenib against HepG2 cell lines via induction of apoptosis and autophagy candidate genes.

• Authors : Nusair, Sara A.¹ (AUTHOR); Galal, Gehan¹ (AUTHOR); Radwan, Sara M.² (AUTHOR)

Subjects: *BEE venom; *ANTINEOPLASTIC agents; *CELL lines

• Source: Egyptian Journal of Medical Human Genetics. 4/8/2024, Vol. 25 Issue 1, p1-9. 9p.

تفاصيل العنوان

Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.

• Authors : Chen, Qiuping¹ (AUTHOR); Sun, Quan² (AUTHOR); Zhang, Jing¹ (AUTHOR)

Subjects: *HEPATOCELLULAR carcinoma; *SORAFENIB; *COST effectivenessCHINA

• Source: PLoS ONE. 3/4/2024, Vol. 19 Issue 3, p1-13. 13p.

تفاصيل العنوان